Slynd® is a progestin only pill, otherwise known as a “POP” that effectively prevents pregnancy.

 

Slynd® is an ideal choice for women who can’t take or don’t wish to take an oral contraceptive containing estrogen.

How is Slynd® different from other estrogen-free pills?

 

 

While there are other oral contraceptives that are estrogen-free, Slynd® is the only one that offers a dosing schedule consisting of 24 active pills, each containing drospirenone 4 mg, and 4 placebo pills.

 

This can help provide a cycle that is more familiar to you.

And, unlike other estrogen-free pills, if you miss or forget to take your Slynd®, you still have 24 hours to make up for the missed dose without having to add other means of back-up birth control.

 

 

 

How is Slynd® different from birth control pills that contain estrogen?

 

 

Oral contraceptives with estrogen have been linked to cardiovascular health issues. Since Slynd® is estrogen free, it does not carry the same safety precautions as oral contraceptives containing estrogen. Of course, always listen to your doctor in terms of safety issues with any medication.

Slynd® offers a 24-hour dosing window

 

 

The goal is to never miss a dose of your oral contraceptive, but if you do, Slynd® can be more forgiving than other progestin-only pills in terms of what you have to do to get back on track with your regular schedule, while ensuring continued pregnancy prevention.

 

 

Slynd® is the first and only POP (Progestin-Only Pill) with a 24-hour intake window similar to COCs (Combined Oral Contraceptives which contain estrogen)

Slynd® is the only estrogen-free oral contraceptive with

24 active pills and 4 placebo pills each cycle — 24 + 4 dosing!

 

 

Slynd® has a monthly dosing schedule that will be familiar to you if you’ve ever used an estrogen-containing oral contraceptive. The Slynd® 24+4 dosing regimen can help you manage your periods and bleeding days to fit your lifestyle and expectations better.

24 white (active) pills 

each containing 4 mg of drospirenone for Week 1 through Week 3 and the first 3 days of Week 4 (Days 1-24)

4 green (placebo) pills

for the last 4 days of Week 4 (Days 25-28)

24 white (active) pills 

each containing 4 mg of drospirenone for Week 1 through Week 3 and the first 3 days of Week 4 (Days 1-24)

4 green (placebo) pills

for the last 4 days of Week 4 (Days 25-28)

References (click to expand)

1. Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. Open Acc J Contracept. 2016;7:43-52. doi: 10.2147/OAJC.S85565
2. Slynd [package insert]. Exeltis USA, Inc.; Florham Park, NJ; 2019.
3. Data on file. Exeltis USA, Inc.; Florham Park, NJ; 2019.
4. Fuhrmann U, Krattenmacher R, Slater ED, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996;54(4):243-251
5. Regidor PA, Schindler AE. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestins: dienogest and drospirenone. Oncotarget. 2017:8 (47): 83334-83342.
6. Vroonen L, Cavalier E, Vranken L, et al. Influence of drospirenone on renin-angiotensin-aldosterone system evaluation. Endocrine Abstracts. 2011;26:12.
7. Slopien R, Milewska E, Rynio P, et al. Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age. Menopause Review. 2018;17(1):1-4. doi: 10.5114/pm.2018.74895
8. Greer JB, Modugno F, Allen G, et al. Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstet Gynecol. 2005;105:731-740.
9. Batur P. Female contraception. Cleveland Clinic Center for Continuing Education. Published December 2016.
10. Glisic M, Shahzad S, Tsoli S, et al. Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis Eur J Prev Cardiol. 2018;25(10):1042-1052. doi: 10.1177/2047487318774847.
11. Duijkers IJM, Heger-Mahn D, Drouin D, et al. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception. 2016:93(4): 303-309.

    X

    Please confirm the following information:

    Your Name*

    Practice Location*

    Your NPN*

    Bitnami